Ballas, Samir K.

Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members

Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA

Hemoglobinopathies and Related DisordersHemophilia Treatment and Research

Cited by 1,599

Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease

Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersBlood transfusion and management

Cited by 1,234

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up

Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology

Hemoglobinopathies and Related DisordersBlood groups and transfusion

Cited by 486

N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease

Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., et al. (2006) · JAMA

Hemoglobinopathies and Related DisordersPulmonary Hypertension Research and Treatments

Cited by 197